公开(公告)号：US20060183734A1

公开(公告)日：2006-08-17

申请号：US11403072

申请日：2006-04-11

申请人： Amedeo Failli ,  Jay Shumsky ,  Thomas Caggiano ,  John Dusza ,  Kevin Memoli

发明人： Amedeo Failli ,  Jay Shumsky ,  Thomas Caggiano ,  John Dusza ,  Kevin Memoli

IPC分类号： A61K31/55 ,  C07D498/02

CPC分类号： C07D471/04 ,  C07D243/14 ,  C07D471/14 ,  C07D487/04 ,  C07D495/04

摘要： The present invention provides compounds of the general formulas: wherein Y is NR or —(CH2)n; R is H or alkyl; “Z” represents optionally substituted phenyl or a 6-membered aromatic ring having one nitrogen atom; “W” represents a optionally substituted phenyl or 5-membered aromatic ring having one nitrogen atom; “X” represents an optionally substituted 5-membered aromatic ring having one sulfur atom; as well as methods and pharmaceutical compositions utilizing these compounds for the inducing temporary delay of urination or treatment of disorders remedied by vasopressin agonist activity, including diabetes insipidus, nocturnal enuresis, nocturia, urinary incontinence, or bleeding and coagulation disorders.

摘要翻译： 本发明提供下列通式的化合物：其中Y是NR或 - （CH 2 CH 2）n。 R是H或烷基; “Z”表示任选取代的苯基或具有一个氮原子的6元芳环; “W”表示具有一个氮原子的任选取代的苯基或5元芳环; “X”表示具有一个硫原子的任选取代的5元芳环; 以及利用这些化合物诱导临时延迟排尿或治疗由加压素激动剂活性（包括尿崩症，夜间遗尿症，夜尿症，尿失禁或出血和凝血障碍）补救的病症的方法和药物组合物。

公开(公告)号：US20050075328A1

公开(公告)日：2005-04-07

申请号：US10980939

申请日：2004-11-04

申请人： Amedeo Failli ,  John Dusza ,  Thomas Caggiano ,  Jay Shumsky ,  Kevin Memoli ,  Eugene Trybulski

发明人： Amedeo Failli ,  John Dusza ,  Thomas Caggiano ,  Jay Shumsky ,  Kevin Memoli ,  Eugene Trybulski

IPC分类号： A61K31/55 ,  A61K31/551 ,  A61K31/5513 ,  A61K31/5517 ,  A61P5/02 ,  A61P13/00 ,  A61P13/02 ,  C07D243/10 ,  C07D243/38 ,  C07D401/06 ,  C07D471/04 ,  C07D471/14 ,  C07D487/04 ,  C07D495/04 ,  C07D487/12

CPC分类号： C07D243/10 ,  C07D243/38 ,  C07D401/06 ,  C07D471/04 ,  C07D471/14 ,  C07D487/04 ,  C07D495/04

摘要： A compound of the formulae (I) or (II): wherein: Y is a moiety selected from NR or —(CH2)n; wherein R is hydrogen or (C1-C6) lower alkyl, and n is 1; represents: (1) a phenyl ring optionally substituted with one or two substituents selected, independently, from the group comprising hydrogen, (C1-C6) lower alkyl, halogen, cyano, CF3, hydroxy, (C1-C6) lower alkoxy, (C1-C6) lower alkoxy carbonyl, carboxy, —CONH2, —CONH[(C1-C6) lower alkyl], —CON[(C1-C6) lower alkyl]2; or (2) a 6-membered aromatic (unsaturated) heterocyclic ring having one nitrogen atom, optionally substituted by (C1-C6) lower alkyl, halogen or (C1-C6) lower alkoxy; represents: (1) a phenyl ring optionally substituted with one or two substituents selected, independently, from the group comprising hydrogen, (C1-C6) lower alkyl, halogen, cyano, CF3, hydroxy, (C1-C6) lower alkoxy, or (C1-C6) lower alkoxy carbonyl, carboxy, —CONH2, —CONH[(C1-C6) lower alkyl], —CON[(C1-C6) lower alkyl]2; or (2) a 5-membered aromatic (unsaturated) heterocyclic ring having one nitrogen atom, optionally substituted by (C1-C6) lower alkyl, (C1-C6) lower alkoxy, or halogen; or (3) a 6-membered aromatic (unsaturated) heterocyclic ring having one nitrogen atom, optionally substituted by (C1-C6) lower alkyl, halogen, or (C1-C6) lower alkoxy; represents a 5-membered aromatic (unsaturated) heterocyclic ring having one sulfur atom, optionally substituted by (C1-C6) lower alkyl, halogen, or (C1-C6) lower alkoxy; R1 is a moiety of the formula and R2, R3, R7, R8 and R9 are, independently, selected from a group consisting of hydrogen, (C1-C3) lower alkyl, OCH3, halogen, CF3, —SCH3, OCF3, SCF3, or CN; or a pharmaceutically acceptable salt, or pro-drug form thereof.

摘要翻译： 式（I）或（II）的化合物：其中：Y是选自NR或 - （CH 2）n的部分; 其中R是氢或（C1-C6）低级烷基，n是1; （C1-C6）低级烷基，卤素，氰基，CF3，羟基，（C1-C6）低级烷氧基，（C1-C6）低级烷氧基，（C1-C6）低级烷氧基，（C1-C6） C 1 -C 6低级烷氧基羰基，羧基-CONH 2，-CONH [（C 1 -C 6）低级烷基]，-CON [（C 1 -C 6）低级烷基] 或（2）任选被（C 1 -C 6）低级烷基，卤素或（C 1 -C 6）低级烷氧基取代的具有一个氮原子的6元芳族（不饱和）杂环; 表示：（1）任选被一个或两个取代基取代的苯环，所述取代基独立地选自氢，（C 1 -C 6）低级烷基，卤素，氰基，CF 3，羟基，（C 1 -C 6）低级烷氧基或 （C 1 -C 6）低级烷氧基羰基，羧基，-CONH 2，-CONH [（C 1 -C 6）低级烷基]，-CON [（C 1 -C 6）低级烷基] 或（2）任选被（C 1 -C 6）低级烷基，（C 1 -C 6）低级烷氧基或卤素取代的具有一个氮原子的5元芳族（不饱和）杂环; 或（3）具有一个氮原子，任选被（C 1 -C 6）低级烷基，卤素或（C 1 -C 6）低级烷氧基取代的6元芳族（不饱和）杂环; 表示任选被（C 1 -C 6）低级烷基，卤素或（C 1 -C 6）低级烷氧基取代的具有一个硫原子的5元芳族（不饱和）杂环; R 1是下式的部分，R 2，R 3，R 7，R 8和R 9独立地选自氢

公开(公告)号：US20060276456A1

公开(公告)日：2006-12-07

申请号：US11502982

申请日：2006-08-11

申请人： Kevin Memoli ,  Amedeo Failli ,  Thomas Caggiano ,  Jay Shumsky ,  Eugene Trybulski ,  John Dusza

发明人： Kevin Memoli ,  Amedeo Failli ,  Thomas Caggiano ,  Jay Shumsky ,  Eugene Trybulski ,  John Dusza

IPC分类号： A61K31/551 ,  C07D487/02

CPC分类号： C07D243/10 ,  C07D243/38 ,  C07D401/06 ,  C07D471/04 ,  C07D471/14 ,  C07D487/04 ,  C07D495/04

摘要： A compound of the formulae (I) or (II): wherein: Y is a moiety selected from NR or —(CH2)n; wherein R is hydrogen or (C1-C6) lower alkyl, and n is 1; represents: (1) a phenyl ring optionally substituted with one or two substituents selected, independently, from the group comprising hydrogen, (C1-C6) lower alkyl, halogen, cyano, CF3, hydroxy, (C1-C6) lower alkoxy, (C1-C6) lower alkoxy carbonyl, carboxy, —CONH2, —CONH[(C1-C6) lower alkyl], —CON[(C1-C6) lower alkyl]2; or (2) a 6-membered aromatic (unsaturated) heterocyclic ring having one nitrogen atom, optionally substituted by (C1-C6) lower alkyl, halogen or (C1-C6) lower alkoxy; represents: (1) a phenyl ring optionally substituted with one or two substituents selected, independently, from the group comprising hydrogen, (C1-C6) lower alkyl, halogen, cyano, CF3, hydroxy, (C1-C6) lower alkoxy, or (C1-C6) lower alkoxy carbonyl, carboxy, —CONH2, —CONH[(C1-C6) lower alkyl], —CON[(C1-C6) lower alkyl]2; or (2) a 5-membered aromatic (unsaturated) heterocyclic ring having one nitrogen atom, optionally substituted by (C1-C6) lower alkyl, (C1-C6) lower alkoxy, or halogen; or (3) a 6-membered aromatic (unsaturated) heterocyclic ring having one nitrogen atom, optionally substituted by (C1-C6) lower alkyl, halogen, or (C1-C6) lower alkoxy; represents a 5-membered aromatic (unsaturated) heterocyclic ring having one sulfur atom, optionally substituted by (C1-C6) lower alkyl, halogen, or (C1-C6) lower alkoxy; R1 is a moiety of the formula and R2, R3, R7, R8 and R9 are, independently, selected from a group consisting of hydrogen, (C1-C3) lower alkyl, OCH3, halogen, CF3, —SCH3, OCF3, SCF3, or CN; or a pharmaceutically acceptable salt, or pro-drug form thereof.